Quick Search
Products Factor IX, Human
| Catalogue number: | F0017-14 |
| Size: | 100U |
| Form: | Supplied as a lyophilized powder in TNBP, Polysorbate 80, PEG, 1.5% Glycine, 160mM sodium chloride, 25mM sodium citrate. Reconstitute with sterile ddH2O (same/more than)100ug/ml, which can then be further diluted to other aqueous solutions. |
| Purity: | (same/more than) 95% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Endotoxin: (same/less than) 0.1ng/ug (IEU/ug). |
| References: | 1. A simple technique to reduce epistaxis and nasopharyngeal trauma during nasotracheal intubation in a child with factor IX deficiency having dental restoration. Delgado AV, Sanders JC, Anesth Analg 2004 Oct;99(4):1056-7, table of contents 2. Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. Sheffield WP, Mamdani A, Gataiance S, Liaw PS, Br J Haematol 2004 Aug;126(4):565-73 3. An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex. Kerschbaumer RJ, Riedrich K, Varadi K, J Biol Chem 2004 Sep 24;279(39):40445-50 4. Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene. Sabatino DE, Armstrong E, Liu YL, Herzog RW, Blood 2004 Nov 1;104(9):2767-74 5. Myocardial infarction during factor IX infusion in hemophilia B: case report and review of the literature. Najaf SM, Malik A, Kazmi K, Ann Hematol 2004 Sep;83(9):604-7 6. Hybrid retroviral vector with MCK enhancers inserted in LTR for stable and specific expression of human factor IX in skeletal muscle. Wang JM, Hou J, Kurachi K, Chin Med J (Engl) 2004 Jun;117(6):893-8. |
Get the Best Promotions
